15 Nov 20 | US | Genentech files a complaint against Centus Biotherapeutics, Fujifilm Kyowa Kirin Biologics, Fujifilm Corp and Kyowa Kirin relating to its proposed bevacizumab biosimilar. Genentech asserts that Centus failed to provide sufficient information for G...

20 Oct 20 | All | Celltrion | The American Journal of Managed Care reported a new study indicates Celltrion's rituximab biosimilar CT-P10 could lower costs and expand patient access to biologic therapy for primary Sjogren syndrome.

20 Oct 20 | EG | Sandoz | Daily News E...

Significant biosimilar activities this week include:

  • 28 Sep 20: Innovent announced its ph III trial of Byvasda® (proposed bevacizumab biosimilar) in combination with Tyvyt® (sintilimab) met its primary endpoints of progression-free survival and overall survival.  In...

Significant biosimilar activities this week include:

  • 31 Aug 20, US: Mylan and Biocon announced the launch of Semglee® (insulin glargine) in vial and pre-filled pen presentations in the US.   Semglee® is indicated for the treatment of adult and pediatric patients wit...

Significant biosimilar activities this week include:

  • June 14: Celltrion presented new data from Phase II trials of a Truxima® (biosimilar rituximab), lenalidomide and acalabrutinib regime for the treatment of relapsed/refractory aggressive B-cell lymphoma.  Celltrio...

Please reload

Biosimilars bulletin 

November 9, 2020

Please reload

Search by tags